Peresolimab, a humanised immunoglobulin G1 monoclonal antibody, was investigated in a phase 2a, randomized, double-blind, placebo-controlled clinical trial for the treatment of moderately to severely active rheumatoid arthritis (RA) (NCT04634253). In this touchIMMUNOLOGY interview, we were delighted to speak with Dr. Paul Emery (University of Leeds, Leeds, UK) around the rationale for targeting the programmed cell death-1 pathway in RA, and the methodology, eligibility criteria and findings from the phase 2 trial.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.’ (Abstract number: L03) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is the rationale for targeting the programmed cell death-1 pathway in rheumatoid arthritis (RA)? (0:21)
- What were the methodology and eligibility criteria of your phase 2 study evaluating peresolimab? (1:15)
- What were the primary and secondary endpoints and how well were they met? (1:56)
- What was the safety profile of peresolimab? (2:43)
- What will be the next steps in the clinical development of peresolimab for RA and for other autoimmune diseases? (3:32)
Disclosures: Paul Emery has disclosures with AbbVie/Abbott, Bristol-Myers Squibb(BMS), AstraZeneca, Eli Lilly and Company, Boehringer-Ingelheim, Galapagos, Gilead, Novartis, Pfizer, Samsung, and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
